I-Mab (NASDAQ:NBP) Lowered to Strong Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of I-Mab (NASDAQ:NBP) from a sell rating to a strong sell rating in a research report released on Monday,Wall Street Zen reports.

Several other brokerages have also recently issued reports on NBP. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of I-Mab in a research note on Thursday, August 20th. Weiss Ratings restated a “sell (d-)” rating on shares of I-Mab in a research note on Thursday, August 27th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, I-Mab has a consensus rating of “Hold” and an average price target of $9.00.

I-Mab Stock Performance

NASDAQ:NBP opened at $1.80 on Monday. The firm has a market cap of $208.17 million, a P/E ratio of -5.00 and a beta of 1.50. The stock’s 50 day simple moving average is $1.84 and its 200-day simple moving average is $2.17. I-Mab has a 12-month low of $1.46 and a 12-month high of $6.79.

I-Mab (NASDAQ:NBP) last released its quarterly earnings results on Thursday, August 20th. The company reported ($0.16) EPS for the quarter. Research analysts forecast that I-Mab will post -0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On I-Mab

An institutional investor recently bought a new stake in I-Mab stock. Brooklyn Investment Group bought a new position in shares of I-Mab (NASDAQ:NBP) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 12,715 shares of the company’s stock, valued at approximately $51,000. 38.38% of the stock is owned by institutional investors and hedge funds.

About I-Mab

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.